What is nanomedicine?

Nanomedicine is the application of nanotechnology to achieve innovation in healthcare. It uses the properties developed by a material at its nanometric scale 10-9 m which often differ in terms of physics, chemistry or biology from the same material at a bigger scale.

Moreover, the nanometric size is also the scale of many biological mechanisms in the human body allowing nanoparticles and nanomaterials to potentially cross natural barriers to access new sites of delivery and to interact with DNA or small proteins at different levels, in blood or within organs, tissues or cells.

Know more

Key reasons to become a member:

Meet new partners and end-users
Share your success stories
Benefit from unique advantages
Shape the future of Nanomedicine in europe
Promote and educate

Know more

ETPN strategic inputs

As a major pan-European industry-oriented initiative, the ETPN aims at strengthening Europe’s capabilities and competitiveness in the area of nanomedicine innovation. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe.

We have contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine.

Know more

ETPN support to innovation

Complementary to its strategic inputs as an ETP to shape and support public funding on the most promising areas of Nanomedicine, the ETPN has designed in 2014 unique technical infrastructures regrouped in a central instrument: the Nanomedicine Translation HUB.

These free of charge services support and accelerate the development of the best Nanomedicine projects from innovative design to clinical development.

Know more

Are you on the Nanomedicine map?

The NanoMed Map provides thorough insights into the nanomedicine community by showing all the actors of the ecosystem in Europe and beyond. It was initiated by NanoMed 2020, CSA project under FP7_Health.

See the map



Latest news

Answer the IPRP survey on Regulatory Requirements and Research Needs for Liposome Products

Sep 3, 2020

Dear colleagues from the European Community of Nanomedicine, we are glad to share with you a 2-week deadline extension for the survey of WG on Nanomedicines of the International Pharmaceutical Regulators Programme (IPRP) about the needs for research & regulation...

Participate to the REFINE survey on regulatory needs for nanomedicine.

Aug 14, 2020

Launched in December 2017, H2020 project REFINE aims to develop a regulatory science framework for nanotechnology-enabled health products. Recently released REFINE’s White Paper summarises main regulatory challenges in the field and provides information on relevant...